Citigroup Maintains Neutral on Integra Lifesciences, Raises Price Target to $19
Integra LifeSciences Holdings Corporation
Integra LifeSciences Holdings Corporation IART | 0.00 |
Citigroup analyst Joanne Wuensch maintains Integra Lifesciences (NASDAQ:
IART) with a Neutral and raises the price target from $16 to $19.
